Protocol Ledger

NCT05918302 · Phase III · RECRUITING

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Interventional Phase III clinical trial protocol NCT05918302 sponsored by Grupo Espanol de Tumores Neuroendocrinos in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-27 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05918302
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05918302
Protocol FieldVerified Registry Value
NCT IdentifierNCT05918302
Consolidated Lead SponsorGrupo Espanol de Tumores Neuroendocrinos
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2023-10-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05918302
Hospital Research SiteLocationSite Profile
Hospital Universitario Virgen del RocíoSeville, SpainOpen Hospital Dossier ->
Hospital General Universitario Gregorio MarañónMadrid, SpainOpen Hospital Dossier ->
Hospital Universitario 12 de OctubreMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI